Innopharma Technology & Horizon 2020 Funding

Horizon 2020 funding

On the 1st March 2019, Innopharma Technology formally commenced an R&D project called SmartCrys. The SmartCrys project will apply Pharma 4.0 technologies and know-how to address key challenges of the pharmaceutical industry related to the manufacturing of high-quality active drug or active pharmaceutical ingredients (APIs) which are formed through crystallisation processes. The project is 24 months in duration and is EU funded (€2.1m) through Horizon 2020 SME instrument. This is a competitive funding process with submitted proposals achieving <5% success which is a testament in itself to the recognition the EU gave to the critical impact of the project.